Nature Communications

Durvalumab plus HAIC-FOLFOX followed by maintenance durvalumab for hepatocellular carcinoma with major portal invasion: phase 2 DurHope study

2026-05-18

Full text

DOI https://doi.org/10.1038/s41467-026-73131-y